MEDDIC, BANT, Challenger, and SPIN all instrument the same layer: the deal and the seller. Your no-decision losses come from the layer beneath them, the buyer's decision state, which none of those frameworks measure. DecisionScope is that diagnostic layer. Not a competing methodology. The instrumentation that makes yours work.

Diagnose a stalled B2B deal by running a four-question diagnostic across four readiness dimensions: Problem Conviction, Evaluation Clarity, Outcome Confidence, Organizational Readiness. Score each dimension 1 or 0. The dimension scoring 1 is the gap killing the deal. Match it to a resolution protocol before sending any follow-up.

Most B2B deals that stall after a successful demo do not die from missing information. They die from missing Outcome Confidence, the buyer's ability to picture herself six months past the purchase using the product successfully. The methodology cannot see this dimension. The dashboard cannot measure it. Here is the diagnosis, and three pipeline moves to surface it before the deal goes silent.

Ninety-six percent of B2B companies are functionally invisible in AI discovery. Fifty-one percent of buyers now start vendor research with an AI chatbot. Sixty-nine percent chose a different vendor based on what the AI told them. The discovery channel your funnel was built for has moved. Here is the diagnosis and the three categories of AI-citation work, in priority order.

Your pipeline looks better than it did two years ago. Better leads. Cleaner ICP fits. And your close rate is the same. The problem isn't your sales execution. You optimized the wrong handoff, and the data now shows exactly where the gap is and how long the window stays open to fix it.

Forty percent of your forecast is dying in a meeting you never attend. Not because the buyer chose a competitor. Because your champion got asked a question they couldn't answer in front of their CFO and went silent. Champion enablement is not a content problem. It is an equipment problem. Here is the protocol.

Sales enablement named buyer indecision as the problem in 2022, then spent four years selling the diagnosis back to revenue leaders as rep training. The research is unambiguous: the bottleneck lives on the buyer's side of the table. Here is how to score the buyer instead of the deal, audit the spend, and stop renewing on a category mismatch.

Your no-decision losses aren't a buyer problem. They're a pricing problem. Your team has spent six months proving your product works without ever making the buyer calculate what another quarter of the current state actually costs. This post names why that question goes unasked, why you haven't mandated it, and what to run before Thursday's pipeline review.

B2B buyers overwhelmed by options are 153% more likely to settle for less. The fix is not more information. It is a decision framework they trust before evaluation starts.

Your pipeline has never looked better. Your close rate has never been worse. The disconnect isn't your team's fault. It's a conviction gap that qualification metrics were never designed to catch.